The worldwide ibuprofen API market outperformed US$ 572.9 Million in 2019 and is slated for a steady development outlook through the span of 2019 – 2029, according to the discoveries of novel Future Market Insights (FMI) research. The essential variables for the development of the Ibuprofen API market incorporate the persistent need for minimal cost NSAID (non-steroidal anti-inflammatory drugs), and time and scale of production facilities.

Expanding API drug deficiencies and amassing teams to defeat these issues, rise of cost-efficient drug producers in different nations and supply of API drugs, essentially in emerging nations, are moreover fuelling ibuprofen API market development.

Download a Sample Report with Table of Contents and Figures:

The pharmaceutical API sector is seeing a considerable crisis in demand and supply of Ibuprofen API, halted manufacturing from significant ibuprofen API makers, supply chain disruption in china moreover directed by dropping sales in India. The unpredictability in Ibuprofen API is because of aspects, for example, less number of contenders, decreased usage proportion, lower margin level, novel higher-estimation prospects in intricate combinations & high-grade API, rate of facility review by FDA, and increase in production limit of through consolidation and mergers.

FMI Studies the COVID-19 Impact on Market

FMI’s study recommends that the present COVID-19 pandemic is having an unfavorable influence on market development. Wuhan, China is the center of API supplies. The region is the epicenter of the COVID-19 outbreak, as such; it has momentarily halted its production facilities. Moreover, China is the outstanding or the lone supplier of APIs incorporating, erythromycin and penicillin, in the world. Distributors and manufacturers in the nation are blaming labor scarcity and logistical barriers because of the COVID-19 pandemic for the delay in transportation and production.

Key Takeaways of Ibuprofen API Market Study

  • Greater center on relieving supply chain pressure because of the demand gap is being undertaken by ramping up manufacturing capacity, upscaling is the primal strategy defined for meeting requirements in the Ibuprofen API landscape.
  • Most of the anti-inflammatory drugs are produced in Asia, particularly in India and China. Around 80% of the overall anti-inflammatory APIs are produced in China and India and most of the APIs made in these nations are outsourced to other emerged regions – Europe and North America.
  • Lower margin level and high upfront price in Ibuprofen API have ensued in a 20-30% cost spike in lower sales and final drug formulations in the earlier year.
  • The Ibuprofen API market is consolidated in nature, with foremost makers accounting for close to 90% of market estimation as 90%. Thus, expanding interest of CMOs and huge-scale API makers are likely to boost the worth creation of the ibuprofen API market.
  • The higher volume covering by contract production organizations in contrast to pharmaceutical nations and amid higher manufacturing capabilities and cost-benefit over pharmaceutical companies is likely to make noteworthy revenue pockets.
  • Growing patient pool devouring non-controlled drugs as OTC is additionally responsible for the development of in-house ibuprofen API usage in East and South Asia.

We offer tailor-made solutions to fit your requirements, request customization@

Lesser labor cost, ample accessibility of raw materials demanded to ibuprofen API are amid the foremost aspects boosting the development of the ibuprofen API market in South Asia. Additionally, favorable regulatory support to set up ibuprofen API production businesses, lesser taxation policies are encouraging the development of the South and East Asia ibuprofen API market.

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends

Contact Us

Mr. Abhishek Budholiya
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44 (0) 20 7692 8790
Press Office:

Leave a comment

Your email address will not be published. Required fields are marked *